Biogen Medical Research
Immunology
Scientific Objectives
The following areas of research are currently being considered:
At this time, Biogen is primarily considering investigator-sponsored Collaborative Research proposals – should you have a study that fits these areas of interest where Biogen’s input on the design could be considered, please feel free to contact medicalresearch@biogen.com or your assigned Biogen Medical Science Liaison to discuss your idea and timeline to submit.
- Pathogenesis:
- Interferon, myeloid cell biology in autoimmunity and inflammatory disease
- Biomarkers of disease activity and treatment response
- Socio-economic burden: systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) health disparity and unmet need in real world
- Treatment patterns and sequencing:
- Real world evidence (RWE) for organ domain specific disease burden
- Burden of standard of care, corticosteroid tapering and steroid-sparing strategies
- Patient centered outcomes including fatigue and cognitive dysfunction
- AI in image analysis and diagnosis of CLE
- Skin of color and CLE - RWE retrospective/prospective studies
- Characterization of CLE subtypes in the clinic
At this time, Biogen is primarily considering investigator-sponsored Collaborative Research proposals – should you have a study that fits these areas of interest where Biogen’s input on the design could be considered, please feel free to contact medicalresearch@biogen.com or your assigned Biogen Medical Science Liaison to discuss your idea and timeline to submit.
- Antibody-mediated rejection (AMR) and microvascular inflammation (MVI) post kidney transplant
- Evaluation of mechanisms in the pathogenesis and pathophysiology of AMR or MVI
- Use of clinical biomarkers or novel strategies to identify patients with AMR or MVI
- Long-term outcomes associated with clinical, histologic, and molecular features of AMR or MVI
- Studies evaluating healthcare-resource utilization or patient-centered outcomes related to AMR or MVI
- Studies identifying socioeconomic and demographic factors associated with barriers to healthcare access among kidney transplant recipients
- Complement-mediated Kidney Disease
- Characterization of burden of disease, unmet need, novel patient reported outcomes scales and meaningful clinical outcomes in patients with complement-mediated kidney disease
- Biomarkers of disease severity and disease progression in patients with C3G, primary IC-MPGN or other complement mediated kidney disease
- Novel clinical and/or imaging study endpoints of disease severity and disease progression in complement mediated kidney disease
- Role of innate immune system in patients with complement mediated kidney disease glomerular diseases
- Epidemiology or natural history of disease that support better understanding of the trajectory of biomarkers/histological/clinical parameters over the course of disease in patients with complement-mediated kidney disease
- Understand potential benefits of C3 inhibition in novel patient populations with complement-mediated glomerular disease
- Understand real-world use of C3 inhibition and long-term outcomes in patients with C3G or primary IC-MPGN
Note to applicants outside the US: All proposals for systemic pegcetacoplan research to be conducted outside the US should be submitted to Sobi.
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Quality of Life (QoL) and effect on Activities of Daily Living (ADL)
- Further characterization and measurement of PNH symptoms (e.g., brain fog)
- Long-term effects of better treatment
Note to applicants outside the US: All proposals for systemic pegcetacoplan research to be conducted outside the US should be submitted to Sobi.
Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee support will be awarded.